JP6762233B2 - 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用 - Google Patents

化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用 Download PDF

Info

Publication number
JP6762233B2
JP6762233B2 JP2016564122A JP2016564122A JP6762233B2 JP 6762233 B2 JP6762233 B2 JP 6762233B2 JP 2016564122 A JP2016564122 A JP 2016564122A JP 2016564122 A JP2016564122 A JP 2016564122A JP 6762233 B2 JP6762233 B2 JP 6762233B2
Authority
JP
Japan
Prior art keywords
substituents
optionally substituted
alkyl
heteroaryl
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016564122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513897A5 (https=
JP2017513897A (ja
Inventor
ソウバージョ ギ
ソウバージョ ギ
ガロー イブ
ガロー イブ
ジングラ ステファーヌ
ジングラ ステファーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal filed Critical Universite de Montreal
Publication of JP2017513897A publication Critical patent/JP2017513897A/ja
Publication of JP2017513897A5 publication Critical patent/JP2017513897A5/ja
Application granted granted Critical
Publication of JP6762233B2 publication Critical patent/JP6762233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016564122A 2014-04-22 2015-04-21 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用 Active JP6762233B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982445P 2014-04-22 2014-04-22
US61/982,445 2014-04-22
PCT/CA2015/050330 WO2015161373A1 (en) 2014-04-22 2015-04-21 Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells

Publications (3)

Publication Number Publication Date
JP2017513897A JP2017513897A (ja) 2017-06-01
JP2017513897A5 JP2017513897A5 (https=) 2018-06-07
JP6762233B2 true JP6762233B2 (ja) 2020-09-30

Family

ID=54331531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564122A Active JP6762233B2 (ja) 2014-04-22 2015-04-21 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用

Country Status (7)

Country Link
US (1) US10647718B2 (https=)
EP (1) EP3134409B1 (https=)
JP (1) JP6762233B2 (https=)
CN (2) CN111620870B (https=)
CA (1) CA2946446C (https=)
ES (1) ES2788977T3 (https=)
WO (1) WO2015161373A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6795493B2 (ja) 2014-09-18 2020-12-02 ウニヴェルシテ ド モントリオール ヒト造血細胞へのウイルス遺伝子導入を増強させるための化合物および方法
WO2017205977A1 (en) * 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
EP3472162B1 (en) * 2016-06-16 2021-11-17 F. Hoffmann-La Roche AG Heteroaryl estrogen receptor modulators and uses thereof
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
SG11201901199WA (en) * 2016-08-18 2019-03-28 Nat Univ Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
CN106727541A (zh) * 2017-02-20 2017-05-31 刘金涛 一种治疗耳肿胀的药物组合物
CN107353288B (zh) * 2017-06-23 2019-10-18 吉林大学 4-乙胺(2-羧基)-9H-嘧啶并[4,5-b]吲哚及其制备方法
CN111885914B (zh) 2017-10-27 2022-05-13 投资健康有限责任公司 使用芴衍生物制造扩增的造血干细胞的组合物和方法
CN112135618A (zh) * 2018-02-20 2020-12-25 蒙特利尔大学 体内介导免疫应答的nk和dc细胞的扩增
KR102329235B1 (ko) * 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
WO2020106059A1 (ko) * 2018-11-21 2020-05-28 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
EP4076466B1 (en) * 2019-12-18 2026-03-11 Universite De Montreal Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds
CA3165561A1 (en) * 2020-01-24 2021-07-29 Satoshi Yamazaki Serum-free medium and culture method suitable for culturing blood cells including human hematopoietic stem cells
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors
US11851430B1 (en) * 2023-09-06 2023-12-26 King Faisal University Pyrido[4,3-B]indole-7-carboxylic acid compounds as CK2 inhibitors
CN120157613A (zh) * 2023-12-15 2025-06-17 山东诚创蓝海医药科技有限公司 多拉韦林中间体及其应用和合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595701B1 (fr) 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
JP2002529502A (ja) 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
WO2000066112A1 (en) 1999-05-03 2000-11-09 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
AU770564B2 (en) 1999-09-10 2004-02-26 Smithkline Beecham Corporation Thrombopoietin mimetics
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1228051A1 (en) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
ES2275567T3 (es) 1999-12-06 2007-06-16 Smithkline Beecham Corporation Mimeticos de4 trombopoietina.
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2004520302A (ja) 2000-12-19 2004-07-08 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
JP2005515173A (ja) * 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
WO2003103686A1 (en) 2002-06-06 2003-12-18 Smithkline Beecham Corporation Thrombopoietin mimetics
AU2003297925A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Thrombopoietin mimetics
MX2008000462A (es) 2005-07-14 2008-03-10 Irm Llc Compuestos heterotetraciclicos como mimeticos de tpo.
KR20080035700A (ko) 2005-08-15 2008-04-23 아이알엠 엘엘씨 Ｔｐｏ 모방체로서의 화합물 및 조성물
JP5249772B2 (ja) * 2005-11-22 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション キナーゼの阻害剤として有用な三環式化合物
WO2007145227A1 (ja) 2006-06-14 2007-12-21 Chugai Seiyaku Kabushiki Kaisha 造血幹細胞増加促進剤
JP2008050355A (ja) 2006-08-21 2008-03-06 Eisai R & D Management Co Ltd 造血幹細胞を増殖、分化および／または循環系内に動員させる医薬組成物および方法
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
US8609411B2 (en) 2007-05-04 2013-12-17 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
AU2008335761B2 (en) 2007-12-13 2014-04-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CN101423517B (zh) 2008-11-28 2011-09-14 浙江大学 γ-咔啉类衍生物及其制备方法和用途
JP2010193879A (ja) 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
US20120157500A1 (en) 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
WO2011159857A1 (en) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
US9198900B2 (en) 2011-11-10 2015-12-01 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment of peritoneal injury using JAK inhibitors
EP2807165B1 (en) * 2012-01-27 2019-05-15 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
CN104781234A (zh) * 2012-05-22 2015-07-15 伊莱利利公司 用于检测神经功能障碍的基于咔啉和咔唑的成像剂
EP2970312B1 (en) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same

Also Published As

Publication number Publication date
CN106414445B (zh) 2020-07-03
CN111620870B (zh) 2023-01-03
CA2946446A1 (en) 2015-10-29
US20170037047A1 (en) 2017-02-09
CA2946446C (en) 2020-11-03
CN111620870A (zh) 2020-09-04
EP3134409A1 (en) 2017-03-01
JP2017513897A (ja) 2017-06-01
CN106414445A (zh) 2017-02-15
EP3134409A4 (en) 2017-10-04
ES2788977T3 (es) 2020-10-23
US10647718B2 (en) 2020-05-12
EP3134409B1 (en) 2020-02-12
WO2015161373A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
JP6762233B2 (ja) 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用
CN104144931B (zh) 嘧啶并[4,5‑b]吲哚衍生物及其在造血干细胞的扩增中的应用
TWI457339B (zh) 稠合雜芳香環吡咯啶酮
TWI662039B (zh) 用於誘發軟骨生成之化合物及組合物
CN109415341B (zh) 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
TW201028153A (en) Compounds that expand hematopoietic stem cells
CN102395589A (zh) 稠合吡咯并吡啶衍生物
KR20060125818A (ko) 치환된 이미다조 고리 시스템 및 방법
CN111417640B (zh) 化合物及其在干细胞和/或祖细胞扩增中的应用
CN116925077A (zh) 吡啶并环类化合物及其制备方法、中间体、组合物和应用
HK1203945B (en) Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
HK40027068A (en) Compounds and use thereof in the expansion of stem cells and/or progenitor cells

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200818

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200908

R150 Certificate of patent or registration of utility model

Ref document number: 6762233

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250